The goal of the collection is to bridge molecular research and clinical application, potentially enhancing the understanding and treatment of these complex diseases, in which several key molecular processes remain to be fully elucidated
10.1016/0376-8716(79)90040-1 173 LiX
[9] Tirzepatida (Mounjaro para diabetes): Este agonista dual GLP-1/GIP se inicia con 2.5 mg semanalmente durante 4 semanas, con aumentos graduales de 2.5 mg cada 4 semanas segn la respuesta clnica, hasta una dosis mxima de 15 mg semanales
Previously approved diabetes drugs were weight neutral or caused weight gain, a concern because obesity is often a co-morbidity of T2DM and can increase the risk for a cardiovascular complication, such as a heart attack or stroke
The research on melanocortin receptors led to the development of Melanotan 2
Quick summary The phrase 'GLP-1 supplements' gets used two very different ways